Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1428MR)

This product GTTS-WQ1428MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1428MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11328MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ15948MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ5655MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ7360MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ4051MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ8756MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ14484MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ9290MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW